Since there were no particular issues with the pre-admission tests, it was decided that I would undergo a prostate biopsy ...

Prostate cancer is the second most commonly diagnosed cancer among men worldwide, with an estimated 1.55 million new cases in ...

Kiszala, the CEO and co-founder of intoDNA, to explore how a breakthrough in understanding DNA damage and repair could ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix”) provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026).

Experts are starting to question whether identifying ductal carcinoma in situ as cancer leads to unnecessary interventions ...

FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting. The designation recognizes the ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), ...

Cancer patients in Lincolnshire can now benefit from a new radiotherapy treatment machine that can help save lives. The ...

Good evening and welcome to Doctors on Call back on our we're back on our 45th season at this time. I'm Dr. Ray Christensen, ...

November 2026 examEven after finishing your study for the Breast Cancer Specialist exam, you cannot determine through knowledge checks alone whether you can verbally explain your judgment when case ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, ...